Acute Myeloid Leukemia News
CRISPR Gene Editing Used to Build 1st Model of AML Progression. Blocking early inflammatory and innate immune signaling is a promising therapeutic target in acute myeloid leukemia (AML), as disruptions in these signaling pathways occur early ... February 18, 2021.
News Archives - Acute Myeloid Leukemia News
Feb 11, 2021 · Magrolimab Achieves Positive Results in Ongoing Phase 1b Trial. News. Gilead Sciences’ investigational therapy magrolimab was well-tolerated and effective in untreated acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy, according to data from a …
Alvocidib - Acute Myeloid Leukemia News
Jan 27, 2020 · Alvocidib is a potential new treatment for patients with acute myeloid leukemia (AML) that is currently being developed by Tolero Pharmaceuticals. The U.S. Food and Drug Administration previously granted alvocidib orphan drug …
OSU Names Leukemia Research Center in Honor of Scientist …
Dec 10, 2020 · Clara D. Bloomfield dedicated her career to finding new treatments for patients with acute myeloid leukemia (AML) and related disorders. To continue the work of its longtime faculty member, Ohio State University (OSU) has named its leukemia research center in honor of the late scientist.
Venclexta (Venetoclax) - Acute Myeloid Leukemia News
Feb 14, 2020 · Learn about Venclexta (ABT-199), an oral medicine used in treating patients with different types of cancer, including some with acute myeloid leukemia.
Cancer Vaccine Galinpepimut-S Prolongs Life of Patients with AML ...
Apr 2, 2020 · Second-line maintenance therapy with the experimental vaccine galinpepimut-S (GPS) significantly prolongs the life of patients with acute myeloid leukemia (AML) who are on their second remission of the disease, according to the final results of a pilot trial, Sellas Life Sciences announced.
Canada Approves Onureg, Oral Chemo for AML Patients in …
Jan 14, 2021 · Health Canada has approved Onureg, an oral formulation of the chemotherapy azacitidine, as the first maintenance therapy for adults with acute myeloid leukemia (AML) who have achieved complete remission after intensive induction chemotherapy.
Rigosertib Combo Fails to Prolong Survival in Higher-risk ...
Sep 21, 2020 · When given alongside best supportive care, rigosertib failed to prolong the survival of patients with higher-risk myelodysplastic syndromes (HR-MDS), a group of blood cancers that often progress to acute myeloid leukemia (AML), a Phase 3 trial has found.
MB-102 CAR T-cell Therapy Dosed to 1st AML Patient in Phase 1/2 …
Nov 9, 2020 · The first patient has been dosed in an open-label Phase 1/2 clinical trial evaluating the safety and efficacy of MB-102 — a CD123-targeted CAR T-cell therapy — in adults with relapsed or refractory acute myeloid leukemia (AML), …
FDA Approves Venclexta Combinations for Newly Diagnosed AML
Oct 22, 2020 · The U.S. Food and Drug Administration (FDA) has granted full approval to Venclexta ( venetoclax ), in combination with Vidaza (azacitidine), Dacogen (decitabine), or low-dose cytarabine, for treating newly diagnosed adults with acute myeloid leukemia (AML).